Posted Jan. 5, 2017 at 2:09 p.m.

Metabolon, Israeli firm team up to study chronic inflamatory diseases

Published: 2017-01-05 14:09:11
Updated: 2017-01-05 14:09:11


Durham-based Metabolon has struck a deal with InnVentis, an Israeli company, to utilize its metabolomics technology as a possible means of improving treatment for various inflammatory diseases.

Financial terms of the deal weren't disclosed.

Metabolon, which recently raised $15 million from a major biotech investor, defines metabolomics as the study of small molecules called metabolites and is a powerful phenotyping technology for precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.

InnVentis is seeking to develop treatments with its technology platform by bringing various "multi-omics" techniques to bear in the fight against such ailments as arthritis.

“We’re working with InnVentis to expand the knowledge we can apply toward chronic inflammatory diseases, starting with studies of rheumatoid arthritis,” said John Ryals, Metabolon's CEO. “Our goal is to use our proprietary technology in conjunction with InnVentis’s platform to provide a more accurate health assessment of patients, as well as clinically useful information. Metabolomics may help answer key biological questions about these complex disorders and improve personalized treatment.”

InnVentis utilizes a variety of machine learning, stringent data and sample collection, analytics and algorithms in seeking effective treatments.

"Generating molecular maps of distinct health and disease states may enable treatment or even prevention of chronic inflammatory diseases, where therapeutic decision is currently based on trial and error.," Metabolon noted in the announcement.

Noted InnVentis CEO Thomas Wickens: “By combining metabolomics with other ‘omics that are ready for exponential scale, InnVentis aims to enable novel, real-time disease management for clinicians and patients. This will include drug responder identification upon first diagnosis, as well as drug dosing management, using a more comprehensive solution built on the Internet of Things (IoT).”

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders